The microbicidal action spectrum of povidone-iodine (PVP-I) is broad – even after short onset times. Unlike local antibiotics and other antiseptic substances, no resistance develops. The high degree of bactericidal efficiency in respect of highly resistant gram-positive pathogenic micro-organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus strains, is particularly significant for hospital hygiene. An in vitro study with 10 genotypically different MRSA isolates showed an optimum bactericidal effect (logarithmic reduction factor value >5) without protein load after just 30 s exposure and even in a dilution of Betaisodona® solution (Mundipharma GmbH) of 1%. With protein load (0.2% albumin), the optimum in microbicidal effectiveness shifts to concentrations ≧10% Betaisodona solution referring to an exposure time of 30 s. Since recent results are now also available on the toxicological safety of PVP-I preparations for the ciliated epithelium of the nasal mucosa and the good tolerability on skin and other mucous membranes is a known factor, a controlled clinical study is currently being carried out to eliminate colonizations of MRSA. Evidence has also recently been produced of the antiviral activity of PVP-I against herpes simplex, adeno- and enteroviruses, as well as its high degree of efficiency against Chlamydia. Hence alongside the classical fields of application, such as the disinfection of the skin and hands, mucosa antisepsis and wound treatment, there are also useful indications for the substance, i.e. rinsing of body cavities and joints and application to the eye.

Keywords:
Antimicrobial effectiveness, Staphylococcus aureus, methicillin-resistant, Intra-articular application, Drug delivery technology
1.
Arakawa Y, Ike Y, Nagasawa M, Shibata N, Doi Y, Shibayama K, Yagi T, Kurata T: Trends in antimicrobial drug resistance in Japan. Emerg Infect Dis 2000;6:572–575.
2.
Chambers HF: The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001;7:178–182.
3.
Fitzner J, Kappstein I, Dziekan G, Gastmeier P, Daschner F, Rüden H: Hygienemassnahmen bei Patienten mit Methicillin-resistentem Staphylococcus aureus (MRSA). Dtsch Med Wochenschr 2000;125:368–371.
4.
Witte W, Braulke C, Heuck D: MRSA – Situation in Deutschland. Hyg Med 2000;25:347–354.
5.
Fleischer W, Reimer K: Povidone-iodine in antisepsis – State of the art. Dermatology 1997;195(suppl 2):3–9.
6.
Niedner R: Cytotoxicity and sensitization of povidone-iodine and other frequently used anti-infective agents. Dermatology 1997;195(suppl 2):89–92.
7.
König B, Reimer K, Fleischer W, König W: Effects of Betaisodona on parameters of host defense. Dermatology 1997;195(suppl 2):42–48.
8.
Deutsche Gesellschaft für Hygiene und Mikrobiologie: Richtlinien für die Prüfung und Bewertung chemischer Desinfektionsverfahren. Stuttgart, Fischer, 1981.
9.
Wichelhaus TA, Schäfer V, Hunfeld KP, Reimer K, Fleischer W, Brade V: Antibakterielle Wirksamkeit von Polyvidon-Iod (Betaisodona) auf hochresistente grampositive Erreger. Zentralbl Hyg Umweltmed 1997/98;200:435–442.
10.
Hierholzer G, Reimer K, Weissenbacher ER: Topische Infektionstherapie und Prophylaxe: Aktueller Stellenwert von PVP-Iod. Stuttgart, Thieme, 1996.
11.
Rudolph P, Reimer K, Mlynski G, Reese M, Kramer A: Modell zur Ermittlung der Nasenverträglichkeit lokaler Antiinfektiva mittels In-vitro-Bestimmung der Ziliaraktivität. Hyg Med 2000;25:500–503.
12.
Williams JD, Waltho CA, Ayliffe GAJ, Lowburry GJL: Trials of five antibacterial creams in the control of nasal carriage of Staphylococcus aureus. Lancet 1967;ii:390–392.
13.
Kramer A, Glück U, Heeg P, Werner HP: Antiseptik; in Kramer A, Heeg P, Botzenhart K (eds): Krankenhaus und Praxishygiene. München, Fischer, 2001, pp 252–268.
14.
Kallenberger A, Kallenberger C, Willenegger H: Experimental investigations on tissue compatibility of antiseptics. Hyg Med 1991;16:383–395.
15.
Ganzer D, Völker L, Follak N, Wolf E, Granzow H: Local effects on the synovial membrane and hyaline articular cartilage after intra-articular instillation of different anti-infective solutions. Arthroskopie 2000;14:31–44.
16.
Wutzler P, Sauerbrei A, Klöcking R, Burckhardt J, Schacke M, Thust R, Fleischer W, Reimer K: Virucidal and chlamydicidal activities of eye drops with povidone-iodine liposome complex. Ophthalmic Res 2000;32:118–125.
17.
Wutzler P, Sauerbrei A, Klöcking R, Reimer K: Virucidal activity and cytotoxicity of a liposomal formulation of povidone-iodine. Antiviral Res 2001;50:A88.
18.
Reimer K, Fleischer W, Brögmann B, Schreier H, Burkhard P, Lanzendörfer A, Gümbel H, Hoekstra H, Behrens-Baumann W: Povidone-iodine liposomes – An overview. Dermatology 1997;195(suppl 2):93–99.
19.
Reimer K, Vogt PM, Brögmann B, Schreier H, Hauser J, Rossbach O, Kramer A, Rudolph P, Bosse B, Fleischer W: An innovative topical drug formulation for wound healing and infection treatment: In vitro and in vivo investigations of a povidone-iodine liposome hydrogel. Dermatology 2000;201:235–241.
20.
Bonowitz A, Schaller M, Laude J, Reimer K, Korting HC: Comparative therapeutic and toxic effects of different povidone iodine (PVP-I) formulations in a model of oral candidosis based on in vitro reconstituted epithelium. J Drug Target 2001;9:75–83.
21.
Ganzer D, Völker L, Reimer K, Fleischer W, Brögmann B, Decker S, Müller G, Kramer A, Granzow H: Efficacy and tolerability of povidone-iodine liposome complex in infected knee joints of rabbits. Clin Microbiol Infect 2001;7(suppl 1):262.
22.
Vogt PM, Hauser J, Rossbach O, Bosse B, Fleischer W, Steinau HU, Reimer K: Polyvinyl pyrrolidone-iodine liposome hydrogel improves epithelialization by combining moisture and antisepsis: A new concept in wound therapy. Wound Repair Regen 2001;9:116–122.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.